An Intact Dopamine Sensitivity in the Brain: A Necessity to Recover Hyperprolactinemia and Galactorrhea in a Female Hemodialysis Patient? by Philipse, E et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/177999
 
 
 
Please be advised that this information was generated on 2017-12-05 and may be subject to
change.
Case Report
An Intact Dopamine Sensitivity in the Brain:
A Necessity to Recover Hyperprolactinemia and
Galactorrhea in a Female Hemodialysis Patient?
Eva Philipse,1 Ester Philipse,2 Theodorus Twickler,1 Amaryllis Van Craenenbroeck,2
Marie Madeleine Couttenye,2 and Luc Van Gaal1
1Department of Endocrinology, University Hospital of Antwerp, Edegem, Belgium
2Department of Nephrology, University Hospital of Antwerp, Edegem, Belgium
Correspondence should be addressed to Eva Philipse; eva.philipse@uza.be
Received 27 February 2017; Accepted 13 June 2017; Published 16 July 2017
Academic Editor: Władysław Sułowicz
Copyright © 2017 Eva Philipse et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
A female hemodialysis patient with galactorrhea due to hyperprolactinemia was treated with different dialysis modalities to assess
the effect on prolactin levels. A single session of both high-flux hemodialysis and hemodiafiltration resulted in decreased prolactin
levels (16,6% and 77,2%, resp.). However, baseline prolactin levels measured immediately before the next dialysis session did
not change markedly. After cabergoline treatment was started, prolactin levels normalized and galactorrhea disappeared. Thus,
dopaminergic inhibition of prolactin secretion might be reduced in patients with end-stage renal disease. This dopaminergic
resistance could be an important mechanism of hyperprolactinemia in hemodialysis patients and its subsequent treatment
strategies.
1. Background
Hyperprolactinemia is the most common cause of galact-
orrhea in women. In patients with end-stage renal disease
(ESRD), the prevalence of hyperprolactinemia in men and
women ranges from 30 to 65%. Nevertheless, little is known
about the mechanism of hyperprolactinemia in this patient
population.
Prolactin has different isoforms with a molecular size
ranging from 23 to 150 kDa.Themonomeric 23 kDa prolactin
isoform is biologically the most active form. One could
speculate that large prolactin isoforms accumulate in patients
with a reduced renal clearance. However, hyperprolactinemia
in patients undergoing renal replacement therapy (RRT) does
not consist abundantly ofmacroprolactin (>50 kDa) isoforms
[1]. However, the long-term effect of RRT on prolactin levels
has never been studied.
As proof of concept, we evaluated prolactin levels in a
female hemodialysis patient with galactorrhea due to hyper-
prolactinemia who underwent different dialysis modalities
to assess the effect of conventional high-flux hemodialysis
(HD) and postdilution hemodiafiltration (HDF) on prolactin
levels.
2. Case Report
A 52-year-old female hemodialysis patient with galactorrhea
due to hyperprolactinemia was treated with cabergoline
(dopamine D
2
receptor agonist). The patient had no residual
renal function. Because of recent cardiothoracic surgery,
cabergoline was discontinued. One month after surgery,
prolactin level was only slightly elevated (48.1 𝜇g/l, reference
level: 2.2–30.3 𝜇g/l) without any complains of galactorrhea.
Cabergoline treatment was not restarted. A few months later,
her dialysis modality was switched fromHD to HDF because
of persistent uremic complaints. Unfortunately, she did not
notice any effect of this change after threemonths and dialysis
modality was reversed to HD. Meanwhile sertraline was
started because of a depression.
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Figure 1: Prolactin levels (𝑦-axis) before and after four-hour HD and HDF session (with or without cabergoline). Prolactin reference range:
2.2–30.3 𝜇g/l.
One month after the cessation of HDF, she presented
again with complaints of galactorrhea. The patients’ thyroid
function was normal (TSH: 0.73mU/l, reference level: 0.36–
3.74mU/l) and she is postmenopausal (FSH: 28.5U/l, post-
menopausal reference level: 19.3–101U/l; LH: 27.4U/l, post-
menopausal reference level: 8.6–61.8U/l; estradiol: 128 ng/l;
postmenopausal reference level: < 138 ng/l). Prolactin levels
immediately before and after a HD session were 131.1 𝜇g/l and
109.3 𝜇g/l, respectively. At the moment of analysis, dialysis
vintage was 94 months and dialysis adequacy targets were
reached (eKT/V 1.64 and URR 78%). Breast ultrasonography
showed no abnormalities and there was no pituitary mass
on nuclear magnetic resonance imaging. Diagnosis of hyper-
prolactinemia due to ESRD in combination with sertraline
therapy was made.
Since galactorrhea reappeared shortly after HDF was
switched to HD, we hypothesized that HDF removes pro-
lactin more effectively than HD. Prolactin levels immediately
before and after a HDF session were 136.9 𝜇g/l and 38.0 𝜇g/l,
respectively. However, after six-week treatment with HDF,
galactorrhea persisted and prolactin levels immediately
before and after a HDF session were 130.7 𝜇g/l and 33.2 𝜇g/l,
respectively. Dialysis adequacy targets on HDF were also
reached (eKT/V 1.81 and URR 83%). Treatment with caber-
goline was restarted, after which galactorrhea resolved and
prolactin levels normalized to 11.5𝜇g/l and 4.4 𝜇g/l before and
after a HDF session, respectively (Figure 1). In all the mea-
sured prolactin levels, there was no macroprolactin present.
3. Discussion
The increase in prolactin levels in patients on RRT could
be partly explained by reduced renal clearance of prolactin
[2, 3]. HD is known to remove small molecules (0–0.5 kDa)
through diffusion. HDF combines diffusion and convec-
tion and improves the clearance of middle-sized molecules
(0,5–15 kDa) such as 𝛽2-microglobulin (11.8 kDa) [4].
Hitherto, no comparison was made between HD and
HDF regarding prolactin clearance. In our patient, we found
significantly lower prolactin levels immediately after a HDF
session compared to a HD session, while dialysis adequacy
between both is quasi-similar. However, baseline prolactin
levels, measured immediately before a HD or HDF session,
did not change markedly and galactorrhea persisted. Stimu-
lation of the D2 receptor was needed to obtain physiological
prolactin levels and total clinical recovery.Delayed disappear-
ance of galactorrhea after normalization of prolactin could
be expected. Al-Husaynei et al. described that galactorrhea
disappeared in 100% of all women with hyperprolactinemic
amenorrhea after eight-week cabergoline treatment [5].
An additional factor contributing to sustained hyper-
prolactinemia in patients with ESRD could be due to an
enhanced prolactin secretion by the pituitary. The secretion
of prolactin is predominantly regulated by dopaminergic
inhibition and this mechanism could be blunted in patients
on RRT, also called lactotrophic resistance [2–4].Themecha-
nism behind that has not been fully elucidated yet (Figure 2).
Sievertsen et al. [6] suggested some mechanisms. First, there
could be a uremic factor which could not be removed by
RRT and interferes with the binding of local dopamine
to its receptor. Second, the quality and/or quantity of the
dopamine receptors could be changed. Finally, modification
in postreceptor metabolism of the dopamine receptor could
be considered [6]. In addition, an increase in prolactin level
is a known secondary effect of sertraline treatment. However,
whether selective serotonin-reuptake inhibitors (SSRIs) and
thus sertraline could cause a clinically overt hyperprolactine-
mia is still controversial [7, 8]. Against that background,
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Figure 2: Concept to explain hyperprolactinemia in end-stage renal failure.
KimandPark describe prevalence of SSRI-inducedhyperpro-
lactinemia of 10.9% [7]. A possible mechanism is that a SSRI
could act as a dopamine-reuptake inhibitor [7, 8].
4. Conclusion
In addition to the reduced renal clearance of prolactin,
lactotrophic resistance is amajor cause of hyperprolactinemia
in patients onRRT. Stimulation of theD
2
receptor, rather than
increased renal clearance alone, is needed for biochemical
and clinical response. It merits further investigation to
elucidate the underlying mechanism.
Conflicts of Interest
The authors declare that they have no conflicts of interest.
References
[1] D. Yavuz, G. Topc¸u, C¸. O¨zener, S. Akalin, and O¨. Sirikc¸i,
“Macroprolactin does not contribute to elevated levels of
prolactin in patients on renal replacement therapy,” Clinical
Endocrinology, vol. 63, no. 5, pp. 520–524, 2005.
[2] G. Ramirez, W. M. O’Neill, H. A. Bloomer, and W. Jubiz,
“Abnormalities in the regulation of prolactin in patients with
chronic renal failure,” The Journal of Clinical Endocrinology &
Metabolism, vol. 45, no. 4, pp. 658–661, 1977.
[3] H. Bry-Gauillard, P. Touraine, M.-F. Mamzer-Bruneel, A.
Simoes-Vaz, F. Kuttenn, and C. Legendre, “Complete regression
of a major hyperprolactinaemia after renal transplantation,”
Nephrology Dialysis Transplantation, vol. 14, no. 2, pp. 466–468,
1999.
[4] P. B. Kerr, A. Argiles, J.-L. Flavier, B. Canaud, and C. M. Mion,
“Comparison of hemodialysis and hemodiafiltration: a long-
term longitudinal study,”Kidney International, vol. 41, no. 4, pp.
1035–1040, 1992.
[5] A. J. Al-Husaynei, I. H. Mahmood, and Z. S. Al-Jubori, “Com-
parison of the effects of cabergoline and bromocriptine in
womenwith hyperprolactinemic amenorrhea,”Middle East Fer-
tility Society Journal, vol. 13, no. 1, pp. 33–38, 2008.
[6] G. D. Sievertsen, V. S. Lim, C. Nakawatase, and L. A. Frohman,
“Metabolic clearance and secretion rates of human prolactin
in normal subjects and in patients with chronic renal failure,”
Journal of Clinical Endocrinology and Metabolism, vol. 50, no. 5,
pp. 846–852, 1980.
[7] S. Kim and Y.-M. Park, “Serum prolactin and macroprolactin
levels among outpatients withmajor depressive disorder follow-
ing the administration of selective serotonin-reuptake inhi-
bitors: A cross-sectional pilot study,” PLoS ONE, vol. 8, no. 12,
Article ID e82749, 2013.
[8] D. La Torre and A. Falomi, “Pharmacological causes of hyper-
prolactinemia,”Therapeutics and Clinical RiskManagement, vol.
3, no. 5, pp. 929–951, 2007.
Submit your manuscripts at
https://www.hindawi.com
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Behavioural 
Neurology
Endocrinology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Disease Markers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
PPAR Research
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
